丁苯酞软胶囊联合阿托伐他汀钙片治疗血管性痴呆患者的临床效果

Abstract
Figure/Table
References (21)
Related Citation (15)

Download: PDF (560 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the effect of Butylphthalide Soft Capsules combined with Atorvastatin Calcium tablets in treatment of patients with vascular dementia. Methods From August 2014 to August 2016, in the First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine, 80 vascular dementia (VD) patient were selected and divided into observation group (40 cases) and control group (40 cases) according to randomization envelope method. The control group was treated with oral Butylphthalide Soft Capsules Tablets therapy，and the observation group were treated with Atorvastatin Calcium Tablets on the basis of the control group. The patients in the each group were treated for 2 months，the clinical curative effect of two groups after treatment were observed and recorded. The related scale of mini-mental state examination (MMSE) and activities of daily living (ADL) were compared between the two groups of observed before and after treatment. Blood lipid levels and superoxide dismutase (SOD) activity levels were compared the two groups before and after treatment. Results After the treatment, the total effective rate of the observation group was significantly higher than the control group, the differences were statistically significant (P < 0.05). After the treatment, the scores of MMSE in two groups were higher than before treatment, and the scores of MMSE in the observation group were significantly higher than the control group, the differences were statistically significant (P < 0.05); the ADL scores in two groups were lower than before treatment, the ADL scores in the observation group was significantly lower than the control group, the differences were statistically significant (P < 0.05). Compared with before the treatment, the TC, TG and LDL-C levels after the treatment significantly improved, and these in the observation group was significantly better than the control group, the differences were statistically significant (P < 0.05); compared with before the treatment, there was no significant difference of HDL-C levels in the control group after the treatment, the difference was not statistically significant (P > 0.05), the HDL-C level in the observation group after the treatment was significantly higher, and this was significantly higher than the control group, the differences were statistically significant (P < 0.05). After the treatment, the activity of SOD in the two groups was higher than that before the treatment, and the activity of SOD in observation group was significantly higher than in the control group, the differences were statistically significant (P < 0.05). There was no obvious adverse reactions observed after treatment in two groups. Conclusion Butylphthalide Soft Capsules combined with Atorvastatin Calcium Tablets has significant clinica effect in VD patients，which can significantly improve the blood lipid level， increase the activity of SOD, and effectively improve VD symptoms in patients with dementia and mental state, improve the quality of life of patients.

Key words： Vascular dementia Butylphthalide Soft Capsules Atorvastatin Calcium Tablets Cognitive function

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	JIANG Ying

Cite this article:

JIANG Ying. Clinical effects of Butylphthalide Soft Capsules combined with Atorvastatin Calcium Tablets in treatment of patients with vascular dementia[J]. 中国医药导报, 2018, 15(14): 42-46.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2018/V15/I14/42

[1] 俞波，吕望强，章群，等.美金刚、阿托伐他汀联合多奈哌齐治疗老年血管性痴呆疗效观察[J].药物流行病学杂志，2017，26（6）：382-338.
[2] 韩颖，崔鹏，王娇兰，等.不同治疗方法对血管性痴呆患者认知功能的影响[J].中国老年学杂志，2013，33（11），2509-2511.
[3] Liu D，Guossev A，Chen J，et al. Atorvastatin reduces neurological deficit and increases synaptogenesis，angiogenesis，and neuronal survival in rats subjected to traumatic brain injury [J]. J Neurotrauma，2004，21（1）：12-32.
[4] 杨卫红，石晓欣，张琼，等.小剂量阿托伐他汀联合阿司匹林对老年患者颈动脉粥样硬化斑块及血清炎症水平影响的研究[J].中国医药导报，2013，10（7）：102-104.
[5] 范凡.丁苯酞联合艾地苯醌治疗血管性痴呆的临床研究[D].石家庄：河北医科大学，2016.
[6] 刘杰.都可喜治疗血管性痴呆患者的临床疗效观察[J].内蒙古民族大学学报，2010，16（2）：99-100.
[7] 彭丹涛，许贤豪，刘江红，等.简易智能精神状态检查量表检测老年期痴呆患者的应用探讨[J].中国神经免疫学和神经病学杂志，2005，12（4）：187-190，211.
[8] 李炳义.丁苯酞和吡拉西坦对血管性痴呆患者血清丙二醛、超氧化物歧化酶、过氧化脂质影响的比较[J].医学综述，2016，22（18）：3695-3697，3701.
[9] 田金洲，韩明向，涂晋文，等.血管性痴呆的诊断、辨证及疗效判定标准[J].北京中医药大学学报，2000，23（5）：16-23.
[10] 刘艳，赵晓玲，王蕾，等.多奈哌齐与尼莫地平联合治疗老年期血管性痴呆的临床观察[J].中华老年心脑血管病杂志，2010，12（6）：488-490.
[11] 卢昌均，周哲屹，刘国成，等.血管性痴呆发病机制的研究进展[J].中华脑科疾病与康复杂志：电子版，2014，4（3）：183-186.
[12] 胡盾，黄新祥，冯亦璞.丁基苯酞对全脑缺血大鼠的纹状体细胞外液嘌呤类代谢物含量的影响[J].药学学报，1996，31（1）：13-17.
[13] Chong ZZ，Feng YP. Effect of 3-N-butylphthalide on reperfusion induced lipid peroxidation following cerebral ischemiain rats and superoxide formation invitro [J]. J Chin Pharm Sci，1999，8（2）：95-99.
[14] 董高翔，冯亦璞.丁基苯酞对局部脑缺血再灌注大鼠线粒体ATPase抗氧化酶活性和脂质过氧化的影响[J].中国医学科学院学报，2002，24（1）：93-97.
[15] 万鹤鸣，王滨.丁基苯酞对血管性痴呆患者血清自由基及血液流变学的影响[J].新乡医学院学报，2011，28（2）：187-189.
[16] 王建民，周冬亮，覃宏伟，等.丁苯酞对血管性痴呆患者血清中细胞因子可溶性凋亡因子抗氧化分子的影响[J].海南医学院学报，2017，23（3）：422-424，428.
[17] 孙乐羽.丁苯酞软胶囊治疗血管性痴呆的临床疗效[J].中国老年学杂志，2013，33（8）：3967-3969.
[18] 赵晓玲，刘艳，李妮等.阿托伐他汀钙治疗血管性痴呆的疗效及安全性观察[J].西部医学，2011，23（3）：476-477，480.
[19] 马勋龙，刘洋贝，刘荣雁,等.依达拉奉联合阿托伐他汀钙对老年血管性痴呆患者血液流变学及颈动脉硬化斑块的影响[J].解放军医药杂志，2017，29（7）：77-81.
[20] 侯德仁，陈坤，王艳，等.丁苯酞治疗血管性痴呆的疗效和作用机制[J].南方医科大学学报，2009，29（3）：574-578.
[21] 李卫征，张慧敏，赵建民，等.丁苯酞软胶囊联合阿托伐他汀钙片治疗血管性痴呆患者的临床观察[J].中国民康医学，2015，（6）：27-28.